The new three-storey construction will be connected to the existing penicillin production plant and will cover an additional domain of 1875 m². It will be dedicated to bulk formulas and penicillins filling and finishing activities for worldwide distribution.
Automation, API generation for production and simplified procedure will allow Sandoz to integrate all production steps into a single procedure in one place, expanding supply capacity and reliability. The expansion will help a double-digit buildup in our long-term penicillin production capacity.
Saynor added: “Minimising production prices, especially in the face of rising energy prices in Europe, is key to our long-term success, but we also want a sustainable market framework in the long term.
“In economic terms, antibiotics in Europe are still largely treated as commodities, but with one big difference: manufacturers have to source at constant value levels, regardless of adjustments in source and demand. We urgently want to replace the operating environment, introduce fundamental concepts such as inflation-linked pricing and tendering with criteria that go beyond value. “
Sandoz is the world leader in generic antibiotics and has been generating Kundl quality antibiotics for 75 years. He remains committed to building this leadership and maintaining a strong source of antibiotics for the patients who count on them.
Disclaimer This press release comprises forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may sometimes be referred to by words such as “forward-looking”, “possibly” , “it will”. Array “plans”, “possibly”, “may also just”, “”, “expects”, “anticipates”, “expects”, “believes”, “committed”, “investigating”, “in preparation”, “release” or similar terms, or through any express or implied discussions relating to possible market positioning approvals, new indications or labeling of the investigational or new products described in this press release, or in connection with the potential long-term earnings of said products. Do not place undue reliance on such statements. These forward-looking statements are based on our existing ideals and expectations regarding long-term events and are subject to known and unknown vital risks and uncertainties. If one or more of these hazards or uncertainties materialize, or the underlying assumptions prove incorrect, actual effects may differ materially from those set forth in forward-looking statements. There can be no guarantee that the investigational or recalled products described in this news release will be shipped or offered for sale or for any additional indication or labeling in any market position or at any particular time. Nor can it be guaranteed that, if discarded, said generic or biosimilar products will be discarded for all indications included on the label of the reference product. There is also no guarantee that those products will be a long-term commercial success. In particular, our expectations in relation to those products may also be affected by, among other things, the uncertainties inherent in the studies and development, adding the effects of clinical trials and additional studies of existing clinical knowledge; regulatory moves or government delays or regulation at times; specific prescription personal tastes of doctors and patients; festival at times, adding prospective approval of extra generic or biosimilar versions of those products; global trends toward containment of charges for fitness services, adding pressures from governments, payers and the general public over pricing and reimbursement and demands for transparency of higher value; the effects of litigation, including intellectual asset litigation or other legal efforts to save you or restrict the sale of your products through Sandoz; general political, economic and business conditions, adding the effects and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, knowledge integrity or production issues; potential or actual breaches of knowledge security and knowledge privacy, or disruptions to our data generation systems, and other hazards and items referenced in Novartis AG’s existing Form 20-F filed with the Commission Stock Exchange and Securities of the United States. Novartis provides the data in this press release as of this date and assumes no legal responsibility to update any forward-looking statements contained in this press release as a result of new data, long-term events or otherwise.
Sandoz, a department of Novartis, is a global leader in generic and biosimilar medicines. Our goal is to create pioneering solutions for patients by creating and commercializing innovative and affordable approaches that address unmet medical needs. Our ambition is to be the world leader Leading and maximum value company in generics. Our broad portfolio of high-quality medicines, covering all areas of primary healing, accounted for sales of $9. 6 billion in 2021.
Sandoz on social media:LinkedIn: https://www. linkedin. com/company/sandozTwitter: https://twitter. com/sandoz_globalFacebook: https://www. facebook. com/sandozglobal/Instagram: https://www. instagram. com/sandozglobal
CEO Richard Saynor on LinkedIn: https://www. linkedin. com/in/richard-saynor/
# # #
© 2022 Benzinga. com. Benzinga provides investment advice. All rights reserved.